Rasayana Therapeutics

Rasayana Therapeutics is a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting the Ras signaling pathway. The company utilizes advanced chemical biology and structural insights to identify allosteric inhibitors that can effectively modulate Ras proteins, which are among the most common drivers of human cancer. By targeting previously "undruggable" sites on the Ras protein and its regulators, Rasayana aims to address significant unmet needs in oncology, particularly for patients with lung, colorectal, and pancreatic cancers. The company's approach focuses on overcoming resistance mechanisms associated with first-generation Ras inhibitors. Founded on research from the Icahn School of Medicine at Mount Sinai, Rasayana operates at the intersection of academic innovation and industrial drug discovery.